MedTrace Logo

Effect of Ile-Pro-Pro (IPP) on Endothelial Function in Patients With Coronary Artery Disease

NCT00924157 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2012-05-25

No results posted yet for this study

Summary

This study will investigate whether the lacto-tripeptide Ile-Pro-Pro (IPP) improves the function of the endothelium in patients with coronary artery disease. The study has a crossover design. Participants will be treated with a protein hydrolysate rich in IPP for 12 weeks and placebo for 12 weeks with a four-week rest period between treatment periods. The investigators will use ultrasound to test the function of the endothelium in the brachial artery before, after 6 weeks, and after 12 weeks of each treatment. Blood will be collected before and after each treatment. The investigators hypothesize that IPP will improve endothelial function.

Conditions

Interventions

DIETARY_SUPPLEMENT

IPP

Protein hydrolysate rich in lacto-tripeptide (IPP) up to 5 to 15 mg/day

OTHER

Placebo

Matching placebo capsules

Sponsors & Collaborators

  • Boston University

    lead OTHER

Principal Investigators

  • Joseph A Vita, MD · Boston University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00924157 on ClinicalTrials.gov